Looking to sell Caidya stock or options?
Caidya operates as a bio-pharmaceutical-based contract research organization (CRO) focused on supporting the global expansion of drugs. The company offers advisory services that cover clinical development plans, regulatory strategies, approval pathways, and clinical trial support. This enables medical companies to enhance the efficiency of their clinical trials, thereby boosting the likelihood of product success.

Brookside Private Equity, LAV (Lilly Asia Fund), Rock Springs Capital, Rubicon Founders, Tairui Investment, Superstring Capital Management, Kaiser Foundation Hospitals, Springhill Fund Asset Management (HK), Harbert Growth Partners, HSG (Hong Kong).